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Abnormalities of mitochondrial metabolism caus-
ing human disease have been recognised for more
than 30 years. They encompass defects of fatty acid
oxidation, tricarboxylic acid cycle enzymes and the
respiratory chain and oxidative phosphorylation
(OXPHOS) system. The ¢rst mutations of mitochon-
drial DNA (mtDNA) were described 10 years ago: in
excess of 80 mtDNA mutations have now been asso-
ciated with a considerable spectrum of human disor-
ders. As mtDNA encodes proteins of the OXPHOS
system, such mutations frequently result in a de¢-
ciency of one or more of the constituent enzymes
(complexes I^V). Inevitably, respiratory chain defects
are the main focus of attention in mitochondrial dis-
eases as they represent by far the commonest known
biochemical de¢ciency of mitochondrial metabolism
causing disease. The study of mitochondrial metab-
olism has recently included neurodegenerative dis-
eases, speci¢cally Parkinson’s disease (PD), Hunting-
ton’s disease (HD) and Alzheimer’s disease (AD).
OXPHOS defects have been described in all these
three. Although their relationship to aetiology in
PD and AD remains unde¢ned, they are likely, at
least in PD, to contribute towards pathogenesis of
neuronal cell death. This topic, and the role of mi-
tochondria in apeptosis, are reviewed in this issue by
Olanow and Tatton, and by Schapira. The recent
characterisation of the protein products involved in
Friedreich’s ataxia (FA), hereditary spastic paraple-
gia (HSP) and hepatolenticular degeneration (Wil-
son’s disease) as nuclear encoded mitochondrial pro-
teins has broadened the spectrum of ‘mitochondrial
disorders’ still further. OXPHOS defects have been
identi¢ed in FA and HSP, but not yet in Wilson’s
disease. The complexity of factors that may a¡ect
respiratory chain function now requires that they
be reclassi¢ed in order to introduce some consistency
of nomenclature and improve our understanding of
the di¡erent mechanisms a¡ecting OXPHOS. A new
classi¢cation is outlined in Table 1.
Primary OXPHOS defects are thus de¢ned as
those caused by mutations of mtDNA or nuclear
genes encoding subunits of complexes I^V. The latter
may include mutations a¡ecting mitochondrial tar-
geting of the protein, i.e. the N-terminus leader se-
quence. Only two nuclear encoded mutations have
been de¢ned to date [1,2]; a further defect in the
import of the Rieske iron sulphur (FeS) centre has
been postulated, but not de¢ned at the molecular
level [3]. As discussed by J.A. Morgan-Hughes and
M. Hanna in this issue, a multitude of di¡erent
mtDNA mutations have been reported including
those involving tRNAs and protein coding genes of
complexes I, IV and V as well as cytochrome b. The
majority of mtDNA mutations involve tRNA genes
either as point mutations or as large scale deletions.
One mutation at bp 1555 in rRNA has been associ-
ated with nonsyndromic deafness and in determining
susceptibility to aminoglycoside induced deafness.
Although new mtDNA mutations will continue to
be described, the real challenge is to understand the
pathogenesis of these mutations. Nuclear back-
ground appears to have some in£uence on the drift
of mutation expression [4] as well as on biochemical
expression [5]. Respiratory chain de¢ciencies may
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also result in increased generation of free radicals as
well as act to lower the apoptotic threshold of cells.
However, much remains to be understood in terms of
the mutational load for biochemical expression and
the mechanisms of cell failure.
Secondary OXPHOS de¢ciencies encompass genet-
ic and environmental factors. Certain abnormalities
of mtDNA have been shown to be secondary to nu-
clear mutations. Autosomal dominant chronic pro-
gressive external ophthalmoplegia (CPEO) has been
mapped to loci on chromosome 3 or 10 in some
families whilst other families are linked to neither.
A¡ected patients have multiple mtDNA deletions.
These contrast with the single mtDNA deletions
found in patients with sporadic CPEO. mtDNA de-
pletion is characterised by onset in infancy of, usu-
ally, liver and renal failure with lactic acidosis.
mtDNA levels in a¡ected tissues may be less than
1% of control. When the depletion is expressed in
culture, enucleation and fusion with control
mtDNA-less (b0) cells results in restoration of
mtDNA levels ^ clearly implying that the primary
defect lies in nuclear DNA. The role of transacting
factors on mtDNA transcription, translation and
replication and their possible involvement in mtDNA
depletion are elegantly and comprehensively re-
viewed in this issue by J.-W. Taanman.
Frataxin and paraplegin de¢ciencies are good ex-
amples of secondary OXPHOS de¢ciency. Both are
mitochondrial proteins, and cause FA and chromo-
some 16-linked HSP respectively. Frataxin de¢-
ciency, caused by an expanded intronic GAA repeat,
results in mitochondrial iron accumulation, a de-
crease in mtDNA levels and severe de¢ciencies in
the activities of complexes I^III, as well as aconitase.
The function of frataxin is not known but it may be
involved in FeS assembly as complexes I^III and
aconitase are all FeS containing proteins. Such a
function might also explain the deposition of iron
in Friedreich’s tissues. The OXPHOS defect and in-
creased iron will probably result in increased oxida-
tive stress and damage which in turn may cause the
decrease in mtDNA levels as well as contribute to
cell damage. The OXPHOS defect associated with
paraplegin de¢ciency has only been de¢ned at the
histochemical level as a cytochrome oxidase defect.
Further analysis will be required to determine the
precise mitochondrial abnormalities in HSP. Wil-
son’s disease is associated with liver failure or extrap-
yramidal dysfunction (including parkinsonism) and is
due to mutations in the gene encoding a mitochon-
drial p-type ATPase [6]. Mitochondrial function has
not been investigated in Wilson’s disease but one
would predict that accumulation of copper would
Table 1
Class I: primary OXPHOS defects
These involve mutations of mtDNA genes or nuclear genes resulting in impaired activity of complexes I^V, e.g.
a. Mutations of mtDNA:
i. large scale deletions, duplications involving protein coding genes and tRNA genes;
ii. mutations of protein coding genes, e.g. point mutations, small rearrangements;
iii. mutations of tRNA and rRNA genes.
b. Mutations of nuclear genes encoding OXPHOS subunits. These would include mutations a¡ecting the gene
promoter, the mature protein or its targeting sequence.
Class II: secondary OXPHOS defects
a. Genetic:
i. abnormalities of mtDNA induced by nuclear gene defects a¡ecting mtDNA transcription, translation or
replication, e.g. autosomal dominant or recessive multiple deletions, or mtDNA depletion;
ii. direct damage to mtDNA or defects of mtDNA repair, e.g. frataxin de¢ciency and oxidative damage in
Friedreich’s ataxia;
iii. defects of the import pathway of nuclear encoded OXPHOS subunits, e.g. membrane receptors, processing
proteins, etc. ;
iv. defects of the assembly of OXPHOS, e.g. chaperone mutations, defects of haem synthesis.
b. Toxic:
i. endogenous, e.g. free radicals including superoxide, nitric oxide, peroxynitrite;
ii. exogenous, e.g. methyl-4-phenyl 1,2,3,6 tetrahydropyridine, 3-nitropropionic acid, malonic acid, isoquinolines.
BBABIO 44697 29-1-99
A.H.V. Schapira / Biochimica et Biophysica Acta 1410 (1999) 99^102100
promote oxidative damage and result in an OX-
PHOS defect predominantly a¡ecting complex IV
(cytochrome oxidase).
Whilst FA, HSP and Wilson’s disease may have
OXPHOS de¢ciencies secondary to mutations in nu-
clear encoded mitochondrial proteins, HD involves
respiratory chain defects that appear to be due to a
non-mitochondrial protein ^ huntingtin. Huntingtin
is a widely expressed protein of unknown function;
an abnormal CAG expansion in the huntingtin gene
produces the mutant protein with a polyglutamine
stretch and causes HD. In HD, there is severe neuro-
nal degeneration in the caudate, probably related to
excitoxicity. De¢ciencies of complexes II^IV and
aconitase have been found in HD caudate [7^10]. It
has been proposed that these defects arise as a result
of mutant huntingtin expression, and nitric oxide,
superoxide and peroxynitrite generation [10]. These
mitochondrial abnormalities, although secondary,
probably play an important role in the pathogenesis
of HD. The role of any mitochondrial defect in AD
is unclear. Whilst there is substantial evidence for
de¢ciency of cytochrome oxidase in AD brain, its
cause is unknown and might be related to oxidative
damage or neuronal downregulation. An earlier re-
port that the complex IV defect was due to mtDNA
mutations [11] has subsequently been shown to be
due to artefact [12]. Bonilla et al. review the possible
role of mitochondrial dysfunction in AD in this is-
sue.
The complex I de¢ciency in PD may be related to
both primary and secondary factors. There is evi-
dence that the complex I de¢ciency may be trans-
ferred with mtDNA from PD patients ^ particularly
those with low complex I activity [13]. This implies
that the defect is determined by a mtDNA abnormal-
ity ^ although does not discriminate between an in-
herited or somatic mutation. In a further proportion
of PD patients, the complex I defect may be second-
ary or be enhanced by other factors, e.g. oxidative
damage or dopamine.
There is evidence that both endogenously gener-
ated and exogenous toxins may impair OXPHOS
function. Some, e.g. superoxide, nitric oxide, have
been alluded to above, others, e.g. isoquinolines,
may also be generated endogenously and inhibit res-
piratory complexes. The endogenous production of
free radicals, secondary mtDNA damage and result-
ing impairment in OXPHOS may explain the mito-
chondrial changes that occur with aging. This area is
reviewed in this issue by G.A. Cortopassi. Exogenous
toxins that produce human disease have provided
valuable clues to the possible role of mitochondrial
dysfunction in the spontaneous disease counterpart.
For instance, MPTP was found to inhibit complex I
and induce parkinsonism in man and other primates.
This stimulated the search for complex I de¢ciency in
PD. 3-Nitropropionic acid induced a choreiform ill-
ness and death in a group of farm workers when
accidentally consumed. This toxin and malonate are
both potent complex II inhibitors and also induce
caudate neuronal degeneration in animals ^ parallel-
ing the biochemical and histological defect in HD
brain.
Some causes of OXPHOS de¢ciency remain puta-
tive. For instance a defect of protein import would
inevitably result in OXPHOS de¢ciency as so many
components are nuclear encoded. However, it may
be that such an abnormality would be incompatible
with life. No doubt additional diseases will be char-
acterised at the molecular level and found to involve
mitochondrial proteins. This is a re£ection not only
of the large number of mitochondrial proteins syn-
thesised, but also of the pivotal role of mitochondria
in cellular metabolism.
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